Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

WT1 and interferon-β-vitamin D association in MS: a longitudinal study.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS.
FDA product review for daclizumab
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Multiple sclerosis review.
Mechanism of action for leflunomide in rheumatoid arthritis.
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis.
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Myeloid cell transmigration across the CNS vasculature triggers IL-1β-driven neuroinflammation during autoimmune encephalomyelitis in mice.
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
CNS vasculitis in a patient with MS on daclizumab monotherapy.
Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment.
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union
Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis.
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Opinion: Focus on preclinical sex differences will not address women's and men's health disparities.
Pattern of remyelination in the CNS.
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.

Pages